

# Reed M Hawkins

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1730295/publications.pdf>

Version: 2024-02-01

11  
papers

2,137  
citations

1163117

8  
h-index

1372567

10  
g-index

11  
all docs

11  
docs citations

11  
times ranked

3036  
citing authors

#	ARTICLE	IF	CITATIONS
1	Androgen receptor activity in T cells limits checkpoint blockade efficacy. <i>Nature</i> , 2022, 606, 791-796.	27.8	162
2	Factors associated with outcomes after a second CD19-targeted CAR T-cell infusion for refractory B-cell malignancies. <i>Blood</i> , 2021, 137, 323-335.	1.4	111
3	Clonal kinetics and single-cell transcriptional profiling of CAR-T cells in patients undergoing CD19 CAR-T immunotherapy. <i>Nature Communications</i> , 2020, 11, 219.	12.8	167
4	Feasibility and efficacy of CD19-targeted CAR T cells with concurrent ibrutinib for CLL after ibrutinib failure. <i>Blood</i> , 2020, 135, 1650-1660.	1.4	222
5	High rate of durable complete remission in follicular lymphoma after CD19 CAR-T cell immunotherapy. <i>Blood</i> , 2019, 134, 636-640.	1.4	127
6	Factors associated with durable EFS in adult B-cell ALL patients achieving MRD-negative CR after CD19 CAR T-cell therapy. <i>Blood</i> , 2019, 133, 1652-1663.	1.4	277
7	The response to lymphodepletion impacts PFS in patients with aggressive non-Hodgkin lymphoma treated with CD19 CAR T cells. <i>Blood</i> , 2019, 133, 1876-1887.	1.4	230
8	Immunotherapy with T-Cells Engineered with a Chimeric Antigen Receptor Bearing a Human CD19-Binding Single Chain Variable Fragment for Relapsed or Refractory Acute Lymphoblastic Leukemia and B-Cell Non-Hodgkin Lymphoma. <i>Blood</i> , 2018, 132, 1415-1415.	1.4	6
9	Factors impacting disease-free survival in adult B cell B-ALL patients achieving MRD-negative CR after CD19 CAR-T cells. <i>Journal of Clinical Oncology</i> , 2018, 36, 7005-7005.	1.6	2
10	Clonal Kinetics and Single Cell Transcriptional Profiling of Adoptively Transferred CD19 CAR-T Cells. <i>Blood</i> , 2018, 132, 702-702.	1.4	1
11	Immunotherapy of non-Hodgkin's lymphoma with a defined ratio of CD8 <sup>+</sup> and CD4 <sup>+</sup> CD19-specific chimeric antigen receptor-modified T cells. <i>Science Translational Medicine</i> , 2016, 8, 355ra116.	12.4	832